
Peter Anthopolos
Examiner (ID: 3971)
| Most Active Art Unit | 1611 |
| Art Unit(s) | 1611 |
| Total Applications | 615 |
| Issued Applications | 326 |
| Pending Applications | 62 |
| Abandoned Applications | 245 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19111078
[patent_doc_number] => 20240122828
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => ALKENONE-BASED FORMULATIONS FOR TOPICAL APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 18/386498
[patent_app_country] => US
[patent_app_date] => 2023-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386498
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/386498 | Alkenone-based formulations for topical applications | Nov 1, 2023 | Issued |
Array
(
[id] => 19777463
[patent_doc_number] => 12226484
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Compositions having improved bioavailability of therapeutics
[patent_app_type] => utility
[patent_app_number] => 18/487486
[patent_app_country] => US
[patent_app_date] => 2023-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 54
[patent_no_of_words] => 188952
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18487486
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/487486 | Compositions having improved bioavailability of therapeutics | Oct 15, 2023 | Issued |
Array
(
[id] => 18953692
[patent_doc_number] => 20240042019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => OPTIMIZED TLR7 LIGANDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/485987
[patent_app_country] => US
[patent_app_date] => 2023-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -137
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485987
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/485987 | OPTIMIZED TLR7 LIGANDS AND USES THEREOF | Oct 11, 2023 | Pending |
Array
(
[id] => 19125623
[patent_doc_number] => 20240130976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => Pharmaceutical Formulation of Odevixibat
[patent_app_type] => utility
[patent_app_number] => 18/476590
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18476590
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/476590 | Pharmaceutical Formulation of Odevixibat | Sep 27, 2023 | Pending |
Array
(
[id] => 20437413
[patent_doc_number] => 12508234
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-30
[patent_title] => Pharmaceutical formulation of odevixibat
[patent_app_type] => utility
[patent_app_number] => 18/475930
[patent_app_country] => US
[patent_app_date] => 2023-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 13786
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18475930
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/475930 | Pharmaceutical formulation of odevixibat | Sep 26, 2023 | Issued |
Array
(
[id] => 19032382
[patent_doc_number] => 20240082197
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY
[patent_app_type] => utility
[patent_app_number] => 18/369616
[patent_app_country] => US
[patent_app_date] => 2023-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 185
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18369616
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/369616 | DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY | Sep 17, 2023 | Abandoned |
Array
(
[id] => 19830891
[patent_doc_number] => 20250082677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-13
[patent_title] => LONG COVID MEDICATION AND METHOD OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/244569
[patent_app_country] => US
[patent_app_date] => 2023-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5110
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244569
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/244569 | LONG COVID MEDICATION AND METHOD OF TREATMENT | Sep 10, 2023 | Abandoned |
Array
(
[id] => 19613016
[patent_doc_number] => 20240398696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => DELIVERY OBJECTS SUITABLE FOR NEEDLE-FREE INJECTION EQUIPMENTS
[patent_app_type] => utility
[patent_app_number] => 18/450648
[patent_app_country] => US
[patent_app_date] => 2023-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18450648
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/450648 | DELIVERY OBJECTS SUITABLE FOR NEEDLE-FREE INJECTION EQUIPMENTS | Aug 15, 2023 | Pending |
Array
(
[id] => 19232097
[patent_doc_number] => 20240189288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/345514
[patent_app_country] => US
[patent_app_date] => 2023-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345514
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/345514 | TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTS | Jun 29, 2023 | Pending |
Array
(
[id] => 18829641
[patent_doc_number] => 20230398165
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => COMPOSITE FIBER SPONGE CONTAINING SULFORAPHANE
[patent_app_type] => utility
[patent_app_number] => 18/333283
[patent_app_country] => US
[patent_app_date] => 2023-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18333283
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/333283 | COMPOSITE FIBER SPONGE CONTAINING SULFORAPHANE | Jun 11, 2023 | Pending |
Array
(
[id] => 18672932
[patent_doc_number] => 20230310383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/206559
[patent_app_country] => US
[patent_app_date] => 2023-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18206559
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/206559 | Method of improving psychosocial health | Jun 5, 2023 | Issued |
Array
(
[id] => 18842618
[patent_doc_number] => 20230405022
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => LIPID-LIKE NANOCOMPLEXES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/205096
[patent_app_country] => US
[patent_app_date] => 2023-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18205096
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/205096 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | Jun 1, 2023 | Pending |
Array
(
[id] => 19541628
[patent_doc_number] => 20240358664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => VIGABATRIN LIQUID PHARMACEUTICAL COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/318697
[patent_app_country] => US
[patent_app_date] => 2023-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18008
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318697
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/318697 | Vigabatrin liquid pharmaceutical composition | May 15, 2023 | Issued |
Array
(
[id] => 18610855
[patent_doc_number] => 20230277585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => ACETIC ACID AND HYPOCHLOROUS ACID COMPOSITIONS FOR TREATMENT OF BIOFILMS AND WOUND CARE
[patent_app_type] => utility
[patent_app_number] => 18/197292
[patent_app_country] => US
[patent_app_date] => 2023-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18197292
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/197292 | ACETIC ACID AND HYPOCHLOROUS ACID COMPOSITIONS FOR TREATMENT OF BIOFILMS AND WOUND CARE | May 14, 2023 | Pending |
Array
(
[id] => 18724242
[patent_doc_number] => 20230338372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE
[patent_app_type] => utility
[patent_app_number] => 18/312375
[patent_app_country] => US
[patent_app_date] => 2023-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312375
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312375 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | May 3, 2023 | Issued |
Array
(
[id] => 19150111
[patent_doc_number] => 11975001
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-07
[patent_title] => Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
[patent_app_type] => utility
[patent_app_number] => 18/312333
[patent_app_country] => US
[patent_app_date] => 2023-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 14059
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312333
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312333 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | May 3, 2023 | Issued |
Array
(
[id] => 19510422
[patent_doc_number] => 20240342108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => GREEN METHOD OF PRODUCING CIRCLE-SHAPED SILVER NANOPARTICLES USING ETHYL ACETATE EXTRACT OF URTICA DIOICA LEAVES
[patent_app_type] => utility
[patent_app_number] => 18/134980
[patent_app_country] => US
[patent_app_date] => 2023-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18134980
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/134980 | GREEN METHOD OF PRODUCING CIRCLE-SHAPED SILVER NANOPARTICLES USING ETHYL ACETATE EXTRACT OF URTICA DIOICA LEAVES | Apr 13, 2023 | Pending |
Array
(
[id] => 18496123
[patent_doc_number] => 20230218667
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
[patent_app_type] => utility
[patent_app_number] => 18/122478
[patent_app_country] => US
[patent_app_date] => 2023-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13463
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18122478
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/122478 | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses | Mar 15, 2023 | Issued |
Array
(
[id] => 19884101
[patent_doc_number] => 12269793
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-08
[patent_title] => Affinity illudofulvene conjugates
[patent_app_type] => utility
[patent_app_number] => 18/175495
[patent_app_country] => US
[patent_app_date] => 2023-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 56
[patent_no_of_words] => 42426
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175495
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/175495 | Affinity illudofulvene conjugates | Feb 26, 2023 | Issued |
Array
(
[id] => 18449382
[patent_doc_number] => 20230190658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => MAIN AGENT UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/112747
[patent_app_country] => US
[patent_app_date] => 2023-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13668
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18112747
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/112747 | MAIN AGENT UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAME | Feb 21, 2023 | Abandoned |